FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,161 | -55.5% | 18,472 | 0.0% | 0.07% | -60.9% |
| Q2 2023 | $87,927 | -16.5% | 18,472 | 0.0% | 0.17% | -11.1% |
| Q1 2023 | $105,290 | -67.6% | 18,472 | -42.7% | 0.19% | -71.5% |
| Q4 2022 | $325,443 | +2.3% | 32,254 | +127.7% | 0.67% | +2.6% |
| Q3 2022 | $318,000 | -14.3% | 14,165 | -4.9% | 0.65% | +60.9% |
| Q2 2022 | $371,000 | -20.9% | 14,889 | +23.1% | 0.40% | +16.1% |
| Q1 2022 | $469,000 | -53.1% | 12,095 | -29.1% | 0.35% | -65.0% |
| Q4 2021 | $999,000 | -15.3% | 17,066 | -14.3% | 0.99% | +12.6% |
| Q3 2021 | $1,180,000 | +372.0% | 19,910 | +623.5% | 0.88% | +472.7% |
| Q4 2020 | $250,000 | – | 2,752 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |